Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Cigna (CI): PBM Reform Cloud Looms, but Scale, EPS Resilience & Strategic Divestitures Anchor the Risk/Reward—What’s the Margin Trajectory and Legislative Exposure from Here?
Cigna’s Q1 FY25 results affirmed its durable operating model, with adjusted EPS of $6.74 beating estimates and prompting a full-year guidance raise to ≥$29.60, despite absorbing a $0.63/sh restructuring charge tied to strategic optimization. Evernorth delivered 14% top-line and 5% earnings growth, led by Specialty & Care Services’ 19% revenue gain and expanding biosimilar access via Accredo, with 2B Express Scripts prescriptions and $38B in client savings reinforcing scale leverage. Cigna Healthcare posted 9% revenue growth, underpinned by Select segment strength (+9% customer growth) and stable ~80% MCR, despite stop-loss drag. GLP-1 initiatives like EnCircleRx and ENGUIDE are building long-term optionality, aligning affordability with outcomes. The Medicare divestiture to HCSC, though slightly dilutive, unlocks capital deployment flexibility, while the $2.6B YTD buyback and tech-led cost cuts demonstrate capital discipline. However, bipartisan PBM reform proposals targeting rebate structures and spread pricing introduce earnings risk, particularly to Evernorth. May 2025 policy disclosures suggesting $715B in Medicaid cuts and potential international reference pricing elevate regulatory overhangs, but with PBM margin compression—not structural dislocation—seen as the base case, core EPS durability remains intact. With Cigna maintaining high-return capital allocation, strong retention, and pricing power, can it preserve Evernorth’s economics and defend $30+ EPS credibility in a reform-heavy policy cycle?
